Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • 3-Deazaneplanocin (DZNep): Epigenetic Modulator Targeting...

    2026-03-16

    3-Deazaneplanocin (DZNep): Epigenetic Modulator Targeting EZH2 in Oncology and Metabolic Disease

    Executive Summary: 3-Deazaneplanocin (DZNep, SKU A1905) is a potent S-adenosylhomocysteine hydrolase (SAHH) inhibitor with a Ki of ~0.05 nM, acting through competitive inhibition with adenosine (APExBIO). DZNep suppresses the histone methyltransferase EZH2, leading to global reduction in H3K27 trimethylation and broad epigenetic changes (Mechanism, Evidence, and Epigenetic Impact). This compound consistently induces apoptosis and cell cycle arrest in AML and hepatocellular carcinoma models (Int. J. Biol. Sci. 2020, DOI: 10.7150/ijbs.41627). DZNep is active in both 2D cultures and xenograft models, with verified solubility limits and stability parameters for experimental use. It is not suitable for ethanol-based formulations and requires storage at -20°C; optimal in vitro concentrations range from 100–750 nM with 24–72 h incubation.

    Biological Rationale

    Epigenetic dysregulation is a hallmark of cancer and metabolic disease. The Polycomb Repressive Complex 2 (PRC2), whose catalytic subunit is EZH2, mediates trimethylation of lysine 27 on histone H3 (H3K27me3), facilitating transcriptional silencing of tumor suppressor genes. Overexpression of EZH2 correlates with aggressive tumor phenotypes and poor prognosis in cancers such as acute myeloid leukemia (AML) and hepatocellular carcinoma (HCC) (Xu et al. 2020). Targeting EZH2-mediated epigenetic marks is thus a validated strategy for interrupting oncogenic signaling and restoring tumor suppressor function. DZNep, by inhibiting SAHH, indirectly suppresses EZH2 activity and H3K27me3 levels, enabling reactivation of silenced regulatory pathways. In metabolic disease models, such as non-alcoholic fatty liver disease (NAFLD), EZH2-dependent chromatin modifications are implicated in lipid and inflammatory gene regulation, positioning DZNep as a chemical probe for mechanistic dissection.

    Mechanism of Action of 3-Deazaneplanocin (DZNep)

    DZNep is a structural analog of neplanocin and competitively inhibits SAHH, resulting in intracellular accumulation of S-adenosylhomocysteine (SAH) and global inhibition of methyltransferases. This leads to rapid depletion of EZH2 protein and subsequent loss of H3K27 trimethylation. The compound’s action is not limited to direct EZH2 inhibition, but it achieves functional EZH2 suppression via upstream metabolic blockade. In cell-based assays, DZNep treatment increases expression of cell cycle regulators (p16, p21, p27, FBXO32) and reduces cyclin E and HOXA9, culminating in cell cycle arrest and apoptosis. In HCC models, DZNep impairs sphere-forming capacity and tumor initiation, key traits of cancer stem/initiating cells. In NAFLD models, DZNep decreases EZH2 levels and activity, increasing lipid accumulation and inflammatory mediators. The compound is water- and DMSO-soluble, crystalline, and requires dissolution protocols that avoid ethanol and ensure complete resuspension (e.g., ultrasonication, gentle warming).

    Evidence & Benchmarks

    • DZNep inhibits SAHH activity with a competitive inhibition constant (Ki) of ~0.05 nM in vitro (APExBIO).
    • In AML cell lines (HL-60, OCI-AML3), DZNep induces apoptosis within 24–72 hours at 100–750 nM, with measurable depletion of EZH2 and H3K27me3 (Xu et al. 2020).
    • In HCC models, DZNep inhibits cell proliferation and sphere formation in a dose-dependent manner and limits tumor growth in mouse xenograft systems (Advanced Epigenetic Modulation).
    • DZNep upregulates p16, p21, and p27, and downregulates cyclin E and HOXA9, markers of cell cycle regulation and differentiation (Mechanism, Evidence, and Epigenetic Impact).
    • In NAFLD mouse models, DZNep administration reduces hepatic EZH2 and increases lipid/inflammatory signaling molecules (Epigenetic Modulator Transformation).
    • Stock solutions are stable at -20°C; DZNep is insoluble in ethanol but dissolves in water (≥17.43 mg/mL) or DMSO (≥17.07 mg/mL) (APExBIO).

    Applications, Limits & Misconceptions

    DZNep is widely used in oncology research for targeting cancer stem cells and sensitizing tumors to chemotherapeutic agents. Its effects on EZH2 make it a valuable tool for dissecting Polycomb-mediated silencing and DNA methylation interplay. In metabolic disease research, DZNep serves as a probe for epigenetic regulation of lipid metabolism and inflammation. However, its broad methyltransferase inhibition requires careful interpretation of downstream effects, as not all observed changes are specific to EZH2 inhibition. Results in non-cancerous models should be contextualized, as DZNep may alter multiple methylation-dependent pathways. The compound is not recommended for ethanol-based protocols, and long-term storage of diluted solutions should be avoided to prevent degradation.

    Common Pitfalls or Misconceptions

    • DZNep does not directly inhibit EZH2 enzymatic activity; its effect is mediated via SAHH inhibition and subsequent protein depletion.
    • It is not selective for EZH2; other methyltransferases may also be affected due to global SAHH blockade.
    • DZNep is insoluble in ethanol; attempted dissolution in ethanol leads to precipitation and experimental failure.
    • Long-term storage of DZNep solutions (>one week) at room temperature or above -20°C reduces potency.
    • Observed biological effects may stem from broad methylation changes, not exclusively from EZH2/H3K27me3 loss.

    For additional scenario-based troubleshooting and data-driven guidance, see this article on experimental obstacles, which this dossier extends by providing updated stability and selectivity data. For a mechanistic deep dive, this review details dual inhibition pathways, while our article updates benchmarks and clarifies experimental boundaries.

    Workflow Integration & Parameters

    DZNep is supplied as a crystalline solid by APExBIO (SKU A1905). Prepare stock solutions at concentrations >10 mM in DMSO or water, using gentle heating (≤37°C) and ultrasonication to facilitate dissolution. Working concentrations for cell-based assays range from 100 to 750 nM, with typical incubation periods of 24 to 72 hours. Avoid ethanol as a solvent. Store solid at -20°C in a desiccated environment. Do not store aqueous or DMSO solutions long-term; prepare fresh aliquots for each experiment. For in vivo models, consult published protocols to determine dosing schedules and vehicle compatibility. Monitor endpoints such as EZH2 protein levels, H3K27me3 status by Western blot, cell viability, apoptosis (e.g., Annexin V/PI), and gene expression changes (p16, p21, p27, FBXO32). For troubleshooting, see data-driven solutions for assay reproducibility.

    Conclusion & Outlook

    3-Deazaneplanocin (DZNep) is a validated chemical tool for reversible epigenetic modulation via SAHH inhibition and EZH2 depletion. Its use in oncology and metabolic disease research is supported by robust preclinical evidence and reproducible protocols. While not EZH2-selective, DZNep’s ability to reactivate silenced regulatory pathways and induce apoptosis in cancer cells makes it indispensable for mechanistic and translational studies. For full technical specifications, refer to the product page. This dossier extends previous reviews by providing updated evidence, workflow parameters, and clarifying misconceptions for advanced research applications.